Adenosine receptor modeling: What does the A2A crystal structure tell us?

Current Topics in Medicinal Chemistry

Volumn 10, Issue 10, 2010, Pages 993-1018

  Dal Ben, D ^a   Lambertucci, C ^a   Marucci, G ^a   Volpini, R ^a   Cristalli, G ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Adenosine receptors; Docking; Homology modeling; Molecular modeling; Mutagenesis; Structure based drug design

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; RHODOPSIN;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; HYDROPHILICITY; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1;

EID: 77953497157     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791293145     Document Type: Article

References (179)

1. Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63, 1256-1272.
2. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 2001, 53, 527-552.
3. Fredholm, B. B.; Arslan, G.; Halldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's Arch. Pharmacol., 2000, 362, 364-374.
4. 2A adenosine receptor bound to an antagonist. Science, 2008, 322, 1211-1217.
5. 1 adenosine receptor. Biochem. Biophys. Res. Commun., 1992, 187, 919-926.
6. 2B receptor from human brain. Biochem. Biophys. Res. Commun., 1992, 187, 86-93.
7. 3 adenosine receptor. Proc. Natl. Acad. Sci. USA, 1993, 90, 10365-10369.
8. 2 receptor. Brain Res. Mol. Brain Res., 1992, 15, 62-66.
9. 2B adenosine receptors. Curr. Top. Med. Chem., 2003, 3, 427-443.
10. Colquhoun, D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol., 1998, 125, 924-947.
11. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci., 1995, 25, 366-428.
12. Costanzi, S.; Vincenzetti, S.; Cristalli, G.; Vita, A. Human cytidine deaminase: a three-dimensional homology model of a tetrameric metallo-enzyme inferred from the crystal structure of a distantly related dimeric homologue. J. Mol. Graph. Model., 2006, 25, 10-16.
13. Kristiansen, K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther., 2004, 103, 21-80.
14. Lomize, A. L.; Pogozheva, I. D.; Mosberg, H. I. Structural organization of G-protein-coupled receptors. J. Comput. Aided Mol. Des., 1999, 13, 325-353.
15. 1 receptor, based on steric, electrostatic, and hydrophobic properties. J. Med. Chem., 1990, 33, 1708-1713.
16. Peet, N. P.; Lentz, N. L.; Meng, E. C.; Dudley, M. W.; Ogden, A. M.; Demeter, D. A.; Weintraub, H. J.; Bey, P. A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors. J. Med. Chem., 1990, 33, 3127-3130.
17. Quinn, R. J.; Dooley, M. J.; Escher, A.; Harden, F. A.; Jayasuriya, H. A computer generated model of adenosine receptors rationalising binding and selectivity of receptor ligands. Nucleosides Nucleotides Nucleic Acids, 1991, 10, 1121-1124.
18. Dooley, M. J.; Quinn, R. J. The three binding domain model of adenosine receptors: molecular modeling aspects. J. Med. Chem., 1992, 35, 211-216.
19. 1 ligands: requirements for receptor affinity. Bioorg. Med. Chem., 1996, 4, 923-934.
20. 1 receptor antagonists. J. Med. Chem., 2002, 45, 4875-4887.
21. Mager, P. P.; Reinhardt, R.; Richter, M.; Walther, H.; Rockel, B. Molecular simulation of 8-styrylxanthines. Drug Des. Discov., 1995, 13, 89-107.
22. 2 agonists. Eur. J. Med. Chem., 1995, 30, 15-25.
23. Henderson, R.; Unwin, P. N. Three-dimensional model of purple membrane obtained by electron microscopy. Nature, 1975, 257, 28-32.
24. Schertler, G. F.; Villa, C.; Henderson, R. Projection structure of rhodopsin. Nature, 1993, 362, 770-772.
25. Unger, V. M.; Hargrave, P. A.; Baldwin, J. M.; Schertler, G. F. Arrangement of rhodopsin transmembrane alpha-helices. Nature, 1997, 389, 203-206.
26. Henderson, R.; Baldwin, J. M.; Ceska, T. A.; Zemlin, F.; Beckmann, E.; Downing, K. H. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J. Mol. Biol., 1990, 213, 899-929.
27. Hibert, M. F.; Trumpp-Kallmeyer, S.; Bruinvels, A.; Hoflack, J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol. Pharmacol., 1991, 40, 8-15.
28. 1 receptor. Drug Des. Discov., 1992, 9, 49-67.
29. 1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis. J. Biol. Chem., 1992, 267, 10764-10770.
30. 2A receptor ligand binding site. J. Neurochem., 1994, 63, 1477-1484.
31. 1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition. J. Biol. Chem., 1994, 269, 27900-27906.
32. 1 adenosine receptor mediates specific agonist binding. J. Biol. Chem., 1994, 269, 2373-2376.
33. 2A receptor. Eur. J. Pharmacol., 1994, 268, 95-104.
34. 3 adenosine receptor. Mol. Pharmacol., 1994, 45, 1101-1111.
35. Baldwin, J. M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 1993, 12, 1693-1703.
36. 2A adenosine receptor. J. Biol. Chem., 1995, 270, 13987-13997.
37. Kyte, J.; Doolittle, R. F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol., 1982, 157, 105-132.
38. 2A receptor. Critical involvement of Glu13 in agonist recognition. Eur. J. Pharmacol., 1996, 310, 269-272.
39. 1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. Mol. Pharmacol., 1996, 50, 1635-1642.
40. 278 in ligand binding and sodium modulation. Biochem. Pharmacol., 2000, 60, 661-668.
41. 2A adenosine receptors and biogenic amine G protein-coupled receptors. J. Med. Chem., 1997, 40, 2588-2595.
42. 2A adenosine receptors are required for ligand recognition. Mol. Pharmacol., 1996, 50, 512-521.
43. 2A adenosine receptor are required for ligand recognition. Mol. Pharmacol., 1996, 49, 683-691.
44. 2A adenosine receptor domain specifically responsible for mediating short-term desensitization. Biochemistry, 1997, 36, 832-838.
45. 1 receptors. Biochem. Pharmacol., 1998, 56, 1437-1445.
46. 3 adenosine antagonists: structural homology and receptor docking. J. Chem. Inf. Comput. Sci., 1998, 38, 1239-1248.
47. 1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J. Med. Chem., 1998, 41, 1456-1466.
48. 3 adenosine receptor antagonists. J. Med. Chem., 1999, 42, 706-721.
49. 3 adenosine receptor antagonists. J. Med. Chem., 1999, 42, 3055-3065.
50. 3 receptor subtypes. J. Med. Chem., 1998, 41, 2835-2845.
51. 1 adenosine receptor. An evaluation of the binding free-energy with ligands. Drug Des. Discov., 1998, 15, 149-156.
52. 1 adenosine receptors. Drug Dev. Res., 2001, 54, 52-65.
53. 1 adenosine receptor antagonists. J. Med. Chem., 2001, 44, 316-327.
54. 1 adenosine receptor. J. Biol. Chem., 1999, 274, 3617-3621.
55. 1 receptor. Eur. J. Pharmacol., 2005, 510, 1-8.
56. 1 receptor in ligand-receptor interaction. Biochem. Pharmacol., 2006, 71, 865-871.
57. 1 adenosine receptor. Biochem. Pharmacol., 2000, 60, 1647-1654.
58. 1 receptor. Biochem. Pharmacol., 2001, 61, 137-144.
59. 2B receptor for 2-(1-Hexynyl)adenosine. Mol. Pharmacol., 2000, 58, 1349-1356.
60. 3 adenosine receptor. Mol. Pharmacol., 2000, 57, 539-545.
61. 3 adenosine receptors by site-directed mutagenesis. Biochem. Biophys. Res. Commun., 2001, 284, 596-601.
62. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289, 739-745.
63. Teller, D. C.; Okada, T.; Behnke, C. A.; Palczewski, K.; Stenkamp, R. E. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry, 2001, 40, 7761-7772.
64. Okada, T.; Fujiyoshi, Y.; Silow, M.; Navarro, J.; Landau, E. M.; Shichida, Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl. Acad. Sci. USA, 2002, 99, 5982-5987.
65. Okada, T.; Sugihara, M.; Bondar, A. N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure. J. Mol. Biol., 2004, 342, 571-583.
66. Yeagle, P. L.; Choi, G.; Albert, A. D. Studies on the structure of the G-protein-coupled receptor rhodopsin including the putative G-protein binding site in unactivated and activated forms. Biochemistry, 2001, 40, 11932-11937.
67. Choi, G.; Landin, J.; Galan, J. F.; Birge, R. R.; Albert, A. D.; Yeagle, P. L. Structural studies of metarhodopsin II, the activated form of the G-protein coupled receptor, rhodopsin. Biochemistry, 2002, 41, 7318-7324.
68. Dal Ben, D.; Lambertucci, C.; Vittori, S.; Volpini, R.; Cristalli, G. GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support. J. Iranian Chem. Soc., 2005, 2, 176-188.
69. 3 receptor as an example. Trends Pharmacol. Sci., 2005, 26, 44-51.
70. Moro, S.; Deflorian, F.; Bacilieri, M.; Spalluto, G. Homology modeling as attractive tool to inspect GPCR structural plasticity. Curr. Pharm. Des., 2006, 12, 2175-2185.
71. Martinelli, A.; Tuccinardi, T. Molecular modeling of adenosine receptors: new results and trends. Med. Res. Rev., 2008, 28, 247-277.
72. 3 adenosine receptor and molecular modeling studies. J. Med. Chem., 2001, 44, 2735-2742.
73. 3 adenosine receptor antagonists. J. Med. Chem., 2002, 45, 770-780.
74. 3 adenosine receptor antagonist. J. Med. Chem., 2002, 45, 3579-3582.
75. 2B adenosine receptor subtypes: a molecular modeling investigation. J. Med. Chem., 2003, 46, 4287-4296.
76. 3 receptor can explain their different biological behavior. J. Mol. Graph. Model., 2003, 21, 253-262.
77. Cristalli, G.; Costanzi, S.; Lambertucci, C.; Taffi, S.; Vittori, S.; Volpini, R. Purine and deazapurine nucleosides: synthetic approaches, molecular modelling and biological activity. Farmaco, 2003, 58, 193-204.
78. Kehraus, S.; Gorzalka, S.; Hallmen, C.; Iqbal, J.; Müller, C. E.; Wright, A. D.; Wiese, M.; Konig, G. M. Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique adenosine derivative. J. Med. Chem., 2004, 47, 2243-2255.
79. 2A selectivity. Eur. J. Med. Chem., 2006, 41, 321-329.
80. 1 adenosine receptor with antinociceptive effects in mice. J. Med. Chem., 2009, 52, 2393-2406.
81. 1 adenosine receptor and its agonist binding site. Proteins, 2004, 54, 705-715.
82. 1 adenosine receptor. Chem Bio Chem, 2004, 5, 841-849.
83. 3 receptor with selectively enhanced affinity for amine-modified nucleosides. J. Med. Chem., 2001, 44, 4125-4136.
84. 3 adenosine receptor. J. Biol. Chem., 2002, 277, 19056-19063.
85. 3 adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J. Med. Chem., 2002, 45, 4471-4484.
86. 3 receptor: agonist induced conformational changes of Trp243. J. Comput. Aided Mol. Des., 2006, 20, 673-684.
87. 3 receptor antagonists. Bioorg. Med. Chem., 2004, 12, 613-623.
88. 6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg. Med. Chem., 2004, 12, 2021-2034.
89. Ohno, M.; Gao, Z. G.; Van Rompaey, P.; Tchilibon, S.; Kim, S. K.; Harris, B. A.; Gross, A. S.; Duong, H. T.; Van Calenbergh, S.; Jacobson, K. A. Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position. Bioorg. Med. Chem., 2004, 12, 2995-3007.
90. 3 adenosine receptor (neoceptor) using tailored nucleoside agonists. J. Med. Chem., 2006, 49, 2689-2702.
91. 3 adenosine receptor. J. Mol. Graph. Model., 2006, 25, 562-577.
92. 3 adenosine receptor agonists, partial agonists, and antagonists. J. Med. Chem., 2006, 49, 7373-7383.
93. 3 adenosine receptor antagonists derived from nucleosides containing a bicycle [3.1.0]hexane ring system. Bioorg. Med. Chem., 2008, 16, 8546-8556.
94. 3 antagonist binding. Chem Med Chem, 2008, 3, 111-119.
95. 3 adenosine receptor antagonists and pharmacophore-based drug design. Neurochem. Int., 2009, 55, 637-642.
96. 3 adenosine receptor. Mol. Pharmacol., 2003, 63, 1021-1031.
97. 3 adenosine receptor to probe interactions between the 2-position of adenosine analogs and Gln167 in the second extracellular loop. Nucleosides Nucleotides Nucleic Acids, 2005, 24, 1507-1517.
98. Liang, Y.; Fotiadis, D.; Filipek, S.; Saperstein, D. A.; Palczewski, K.; Engel, A. Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J. Biol. Chem., 2003, 278, 21655-21662.
99. 3 adenosine receptor. J. Mol. Graph. Model., 2006, 25, 549-561.
100. 1 adenosine receptor and study of the mechanisms of its selective ligand binding. Dokl. Biochem. Biophys., 2002, 386, 271-274.
101. 2A adenosine receptor. Dokl. Biochem. Biophys., 2003, 389, 94-97.
102. 2B adenosine receptor and an analysis of the binding modes of its selective ligands. Mendeleev Commun., 2002, 12, 211-212.
103. 2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations. Mol. Pharmacol., 2004, 65, 702-710.
104. 2B receptor. J. Pharmacol. Exp. Ther., 2007, 320, 637-645.
105. 2B receptor antagonists. J. Med. Chem., 2005, 48, 6813-6820.
106. 1 adenosine receptors agonists: a case study. J. Comput. Aided Mol. Des., 2003, 17, 39-51.
107. Cappellacci, L.; Franchetti, P.; Pasqualini, M.; Petrelli, R.; Vita, P.; Lavecchia, A.; Novellino, E.; Costa, B.; Martini, C.; Klotz, K.-N.; Grifantini, M. Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. J. Med. Chem., 2005, 48, 1550-1562.
108. 1 adenosine receptors. Eur. J. Med. Chem., 2007, 42, 1-9.
109. 1 bovine receptor model. ChemMedChem, 2008, 3, 898-913.
110. 2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem., 2003, 278, 46741-46749.
111. 2A agonists and antagonists. J. Med. Chem., 2003, 46, 4847-4859.
112. 2A adenosine receptor and its agonists. Chem. Biol., 2005, 12, 237-247.
113. 2A adenosine receptor antagonists. ARKIVOC, 2006, 8, 74-82.
114. 2A adenosine receptor homodimer. Bioorg. Med. Chem. Lett., 2008, 18, 4312-4315.
115. Moro, S.; Deflorian, F.; Spalluto, G.; Pastorin, G.; Cacciari, B.; Kim, S. K.; Jacobson, K. A. Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chem. Commun., (Camb.) 2003, 2949-2956.
116. Moro, S.; Deflorian, F.; Bacilieri, M.; Spalluto, G. Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity. Curr. Pharm. Des., 2006, 12, 2175-2185.
117. 3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies. J. Med. Chem., 2004, 47, 3580-3590.
118. Pastorin, G.; Bolcato, C.; Cacciari, B.; Kachler, S.; Klotz, K.-N.; Montopoli, C.; Moro, S.; Spalluto, G. Synthesis, biological and modeling studies of 1,3-di-n-propyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as adenosine receptor antagonists. Farmaco, 2005, 60, 643-651.
119. 3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl-and 2-carboxy-substituted derivatives. J. Med. Chem., 2005, 48, 7932-7945.
120. 3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J. Med. Chem., 2006, 49, 3916-3925.
121. 3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations. J. Med. Chem., 2006, 49, 1720-1729.
122. 3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study. J. Med. Chem., 2007, 50, 6596-6606.
123. 3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J. Med. Chem., 2007, 50, 4061-4074.
124. 3 adenosine receptor antagonists. Bioorg. Med. Chem., 2008, 16, 6086-6102.
125. Bolcato, C.; Cusan, C.; Pastorin, G.; Spalluto, G.; Cacciari, B.; Klotz, K.-N.; Morizzo, E.; Moro, S. Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes. Purinergic Signal, 2008, 4, 39-46.
126. 3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J. Med. Chem., 2009, 52, 2407-2419.
127. 3 adenosine receptor antagonists: pyrazolo [4,3-e]1,2,4-triazolo [1,5-c]pyrimidine derivatives as a key study. J. Med. Chem., 2005, 48, 152-162.
128. 2A receptor. J. Chem. Inf. Model., 2008, 48, 350-363.
129. 3 adenosine receptor ligands. Purinergic Signal, 2006, 2, 589-594.
130. 3 adenosine receptor. J. Med. Chem., 2007, 50, 1222-1230.
131. 3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo [3,4-c]quinoline series: molecular docking analysis and pharmacological studies. Bioorg. Med. Chem., 2009, 17, 401-410.
132. 3 receptor antagonists. An approach to the optimization of protein models. J. Med. Chem., 2006, 49, 4085-4097.
133. 3 adenosine receptor antagonists. J. Med. Chem., 2007, 50, 5676-5684.
134. 3 adenosine receptor antagonists. Bioorg. Med. Chem., 2008, 16, 10281-10294.
135. Ivanov, A. A.; Palyulin, V. A.; Zefirov, N. S. Computer aided comparative analysis of the binding modes of the adenosine receptor agonists for all known subtypes of adenosine receptors. J. Mol. Graph. Model., 2007, 25, 740-754.
136. 1 adenosine receptor reengineered for orthogonal recognition by tailored nucleosides. Biochemistry, 2007, 46, 7437-7448.
137. 2B adenosine receptor. J. Med. Chem., 2007, 50, 1810-1827.
138. 2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists. J. Med. Chem., 2008, 51, 2088-2099.
139. Jacobson, K. A.; Kim, S. K.; Costanzi, S.; Gao, Z. G. Purine receptors: GPCR structure and agonist design. Mol. Interv., 2004, 4, 337-347.
140. Costanzi, S.; Ivanov, A. A.; Tikhonova, I. G.; Jacobson, K. A. Structure and function of G protein-coupled receptors studied using sequence analysis, molecular modeling and receptor engineering: adenosine receptors. Front. Drug Des. Discov., 2007, 3, 63-79.
141. Moro, S.; Gao, Z. G.; Jacobson, K. A.; Spalluto, G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev., 2006, 26, 131-159.
142. 2A adenosine receptor agonists and antagonists. ChemMedChem, 2007, 2, 260-281.
143. 2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Curr. Pharm. Des., 2008, 14, 1525-1552.
144. Muller, G. Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach. Curr. Med. Chem., 2000, 7, 861-888.
145. Gershengorn, M. C.; Osman, R. Minireview: Insights into G protein-coupled receptor function using molecular models. Endocrinology, 2001, 142, 2-10.
146. Shacham, S.; Topf, M.; Avisar, N.; Glaser, F.; Marantz, Y.; Bar-Haim, S.; Noiman, S.; Naor, Z.; Becker, O. M. Modeling the 3D structure of GPCRs from sequence. Med. Res. Rev., 2001, 21, 472-483.
147. Archer, E.; Maigret, B.; Escrieut, C.; Pradayrol, L.; Fourmy, D. Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? Trends Pharmacol. Sci., 2003, 24, 36-40.
148. Bosch, L.; Iarriccio, L.; Garriga, P. New prospects for drug discovery from structural studies of rhodopsin. Curr. Pharm. Des., 2005, 11, 2243-2256.
149. Kristiansen, K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther., 2004, 103, 21-80.
150. Fanelli, F.; De Benedetti, P. G. Computational modeling approaches to structure-function analysis of G protein-coupled receptors. Chem. Rev., 2005, 105, 3297-3351.
151. Paiva, A. C.; Oliveira, L.; Horn, F.; Bywater, R. P.; Vriend, G. Modeling GPCRs. Ernst Schering Found. Symp. Proc., 2006, 23-47.
152. Shi, L.; Javitch, J. A. A role for information collection, management, and integration in structure-function studies of G-protein coupled receptors. Curr. Pharm. Des., 2006, 12, 1771-1783.
153. Poulsen, S. A.; Quinn, R. J. Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem., 1998, 6, 619-641.
154. Flower, D. R. Modelling G-protein-coupled receptors for drug design. Biochim. Biophys. Acta, 1999, 1422, 207-234.
155. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem, 2002, 3, 928-944.
156. Becker, O. M.; Shacham, S.; Marantz, Y.; Noiman, S. Modeling the 3D structure of GPCRs: advances and application to drug discovery. Curr. Opin. Drug Discov. Dev., 2003, 6, 353-361.
157. Patny, A.; Desai, P. V.; Avery, M. A. Homology modeling of G-protein-coupled receptors and implications in drug design. Curr. Med. Chem., 2006, 13, 1667-1691.
158. Lundstrom, K. Latest development in drug discovery on G protein-coupled receptors. Curr. Protein Pept. Sci., 2006, 7, 465-470.
159. Goddard, W. A., 3rd; Abrol, R. 3-Dimensional structures of G protein-coupled receptors and binding sites of agonists and antagonists. J. Nutr., 2007, 137, 1528S-1538S.; discussion 1548S.
160. Filizola, M.; Weinstein, H. The study of G-protein coupled receptor oligomerization with computational modeling and bioinformatics. FEBS J., 2005, 272, 2926-2938.
161. Fanelli, F.; De Benedetti, P. G. Inactive and active states and supramolecular organization of GPCRs: insights from computational modeling. J. Comput. Aided Mol. Des. 2006, 20, 449-461.
162. Reggio, P. H. Computational methods in drug design: modeling G protein-coupled receptor monomers, dimers, and oligomers. AAPS J., 2006, 8, E322-336.
163. Franco, R.; Casado, V.; Cortes, A.; Ferrada, C.; Mallol, J.; Woods, A.; Lluis, C.; Canela, E. I.; Ferre, S. Basic concepts in G-protein-coupled receptor homo-and heterodimerization. Scientific WorldJournal, 2007, 7, 48-57.
164. Vohra, S.; Chintapalli, S. V.; Illingworth, C. J.; Reeves, P. J.; Mullineaux, P. M.; Clark, H. S.; Dean, M. K.; Upton, G. J.; Reynolds, C. A. Computational studies of family A and family B GPCRs. Biochem. Soc. Trans., 2007, 35, 749-754.
165. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human 2 adrenergic G-protein-coupled receptor. Nature, 2007, 450, 383-387.
166. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human 2-adrenergic G protein-coupled receptor. Science, 2007, 318, 1258-1265.
167. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Yao, X. J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR engineering yields high-resolution structural insights into 2-adrenergic receptor function. Science, 2007, 318, 1266-1273.
168. 2-adrenergic receptor. Structure, 2008, 16, 897-905.
169. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a 1-adrenergic G-protein-coupled receptor. Nature, 2008, 454, 486-491.
170. 2-adrenergic-based homology models through the docking studies. J. Comput. Chem., 2009, 30, 14-32.
171. 2A adenosine receptor crystallographic structure. J. Med. Chem., 2009, 52, 3284-3292.
172. 2A receptor. J. Comput. Aided Mol. Des., 2009, 23, 807-828.
173. 2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease. ChemMedChem, 2009, 4, 1010-1019.
174. 2B receptors ligands. Bioorg. Med. Chem., 2009, 17, 2812-2822.
175. 3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. J. Med. Chem., 2009, 52, 7640-7652.
176. 3 adenosine receptor-selective nucleosides containing a bicycle [3.1.0]hexane ring system. J. Med. Chem., 2009, 52, 7580-7592.
177. Olah, M. E.; Stiles, G. L. The role of receptor structure in determining adenosine receptor activity. Pharmacol. Ther., 2000, 85, 55-75.
178. 1 adenosine receptor. Mol. Pharmacol., 2001, 59, 1187-1195.
179. Mustafi, D.; Palczewski, K. Topology of class A G protein-coupled receptors: insights gained from crystal structures of rhodopsins, adrenergic and adenosine receptors. Mol. Pharmacol., 2009, 75, 1-12.